Clinical positioning of Voriconazole, Posaconazole, and Isavuconazole in the treatment of Invasive Pulmonary Aspergillosis: A Global Real-World Database Study. (PubMed, J Glob Antimicrob Resist) - Aug 15, 2026 - "No significant differences in all-cause mortality were observed among the three drugs. Despite the higher baseline risk in the PSCZ and ISCZ groups, the outcomes were comparable to those in the VRCZ group, suggesting that these agents are effective alternatives in high-risk real-world settings. PSCZ and ISCZ are valuable options in personalized medicine. Therefore, further prospective studies are warranted."
Journal • Real-world evidence • Pulmonary Disease • Renal Disease • Respiratory Diseases
|
|
Eriko Hashimoto; Sayaka Yoshida; Taito Kitano
|